Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10615877 | 0.79 | KDM4E (0.33) | — | |
| SCHEMBL18545242 | 0.72 | MAP3K14 (0.33) | — | |
| SCHEMBL3628793 | 0.72 | MAP3K14 (0.33) | — | |
| SCHEMBL455753 | 0.72 | — | — | |
| SCHEMBL2548921 | 0.69 | CRBN (0.36) | — | |
| SCHEMBL2548118 | 0.69 | CRBN (0.36) | — | |
| SCHEMBL21880340 | 0.69 | CRBN (0.42) | GAA | |
| SCHEMBL9250982 | 0.68 | MGAM (0.36) | MGAMCA1CA2GAASI | |
| SCHEMBL17297713 | 0.67 | MGAM (0.36) | MGAMCA1CA2GAASI | |
| SCHEMBL24565306 | 0.67 | MGAM (0.34) | MGAMCA1CA2GAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615886-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | Warner-Lambert Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050137215-A1 | [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions | GUZZO PETER R (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2004092134-A1 | [C]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137215-A1 | [C]-fused bicyclic proline derivatives and their use for treating arthritic conditions | PPIC, PRAP1, PRRC2C | MGAM 4690/4885CA1 303/4885CA2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.